HeyJaredAbigail Beaney
- Indexed articles, last 90 days
- 6
- Latest publication
- Sep 15, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 15, 2026
Latest articles
Vera set up for full approval for Trutakna in IgAN with Phase III win (opens the original)
Read excerpt
Vera Therapeutics looks well placed for full approval of Trutakna (atacicept-vymj) in primary IgA nephropathy (IgAN) after successful confirmatory data. In the Phase III ORIGIN 3 trial (NCT04716231), patients treated with Trutakna saw a 0.1mL/min/1.73m2 reduction in mean estimated glomerular filtration rate (eGFR) change from baseline at 52 weeks, compared with a 5.7mL/min/1.73m2 reduction in the placebo group. Looking longer term, the annualised eGFR slope through 104 weeks was just a 0.6 drop
Argenx’s stock rises on Phase III autoimmune myositis victory (opens the original)
Read excerpt
Argenx's stock opened 8.9% up after a Phase III trial of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis met its primary endpoint. In the Phase III ALKIVIA trial (NCT05523167), patients from the combined immune-mediated necrotising myopathy (IMNM) and dermatomyositis (DM) population treated with Vyvgart Hytrulo demonstrated a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) compared to placebo after 52 we
China’s growth continues as country becomes clinical trial powerhouse (opens the original)
Read excerpt
As China's powerhouse status grows even bigger in the clinical trial space, industry leaders are set to come together to discuss how the country will continue to grow. Arena International's Outsourcing in Clinical Trials (OCT) and Clinical Trial Supply (CTS) China conference will return for its second year in September 2026. Taking place in Suzhou, China on 8 and 9 September, industry leaders will discuss emerging trends, collaboration, regulation and more. The agenda includes a keynote session
BioVie stock sinks on Phase IIb Parkinson’s trial data (opens the original)
Read excerpt
BioVie's stock crashed after the biotech released data from its Phase IIb Parkinson's disease trial that used a unique composite measure. The SUNRISE-PD study (NCT06757010) was a multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept of bezisterim, an oral small-molecule, in patients with early-stage Parkinson's disease who had not previously been treated with carbidopa/levodopa. The primary endpoint of the study was change i
MapLight Therapeutics stock crashes on Phase II schizophrenia data (opens the original)
Read excerpt
MapLight Therapeutics' stock crashed by more than 70% after the release of data from its Phase II schizophrenia trial, despite the study meeting its primary endpoint. In the Phase II ZEPHYR trial (NCT07038876), ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), demonstrated a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.